MacroGenics Company Profile (NASDAQ:MGNX)

Analyst Ratings

Consensus Ratings for MacroGenics (NASDAQ:MGNX) (?)
Ratings Breakdown: 1 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Buy (Score: 2.89)
Consensus Price Target: $40.25 (34.35% upside)

Analysts' Ratings History for MacroGenics (NASDAQ:MGNX)
Show:
DateFirmActionRatingPrice TargetActions
6/30/2016Morgan StanleyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2016BTIG ResearchReiterated RatingBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Leerink SwannReiterated RatingOutperform$47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016WedbushReiterated RatingOutperform$52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Citigroup Inc.Lower Price Target$37.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/18/2016Janney Montgomery ScottInitiated CoverageBuy$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/5/2015Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/6/2015Stifel NicolausReiterated RatingBuy$51.00 -> $56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for MacroGenics (NASDAQ:MGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016Q216($0.02)$27.22 millionN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2016Q1($0.67)($0.88)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q4($0.60)($0.88)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2015Q2($0.44)($0.71)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015$0.87($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2015($0.36)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014($0.42)($0.14)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014($0.29)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014($0.09)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013$0.15$0.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for MacroGenics (NASDAQ:MGNX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165($0.92)($0.46)($0.70)
Q2 20164($0.91)($0.48)($0.69)
Q3 20164($0.92)($0.51)($0.75)
Q4 20164($1.02)($0.54)($0.83)
Q2 20171($0.83)($0.83)($0.83)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for MacroGenics (NASDAQ:MGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for MacroGenics (NASDAQ:MGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/1/2016Jon Marc WiggintonCMOSell5,000$27.22$136,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016Lynn CilinskiVPSell8,922$27.22$242,856.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2016Lynn CilinskiVPSell5,000$25.00$125,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Paulo F CostaDirectorBuy10,000$17.20$172,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Jon Marc WiggintonSVPSell10,000$29.64$296,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/23/2015Lynn CilinskiVPSell6,921$35.00$242,235.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Ezio BonviniVPSell3,117$31.44$97,998.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Ezio BonviniVPSell6,233$25.21$157,133.93View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Jon Marc WiggintonSVPSell5,000$21.11$105,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2015Ezio BonviniVPSell2,400$38.09$91,416.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Jon Marc WiggintonSVPSell5,000$37.15$185,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Lynn CilinskiVPSell6,921$37.15$257,115.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2015Ezio BonviniVPSell6,497$38.07$247,340.79View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2015Ezio BonviniVPSell6,097$38.08$232,173.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015Ezio BonviniVPSell13,054$38.14$497,879.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Ezio BonviniVPSell6,233$34.01$211,984.33View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015Ezio BonviniVPSell6,233$30.24$188,485.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Ezio BonviniVPSell6,233$33.98$211,797.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Jon Marc WiggintonSVPSell5,000$31.04$155,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014Kathryn E SteinSVPSell10,946$37.00$405,002.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Eric Blasius RisserVPSell10,000$33.50$335,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Kathryn E SteinSVPSell10,946$33.00$361,218.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Eric Blasius RisserVPSell10,000$27.75$277,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Kathryn E SteinVPSell10,946$27.00$295,542.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Kathryn E SteinVPSell25,301$23.30$589,513.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Eric Blasius RisserVPSell25,000$23.80$595,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Jon Marc WiggintonVPSell5,000$20.48$102,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Eric Blasius RisserVPSell8,316$20.89$173,721.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Jon Marc WiggintonVPSell5,000$20.52$102,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2014Eric Blasius RisserVPSell8,000$21.84$174,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2014Kathryn E SteinVPSell10,946$19.75$216,183.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Edward HurwitzDirectorSell308,513$36.50$11,260,724.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2013Kenneth GalbraithDirectorBuy46,875$16.00$750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for MacroGenics (NASDAQ:MGNX)
DateHeadline
07/27/16 03:48 PMMacroGenics Announces Date of Second Quarter 2016 Financial Results Conference Call - [at noodls] - Rockville, MD, July 27, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 3, 2016, the Company will release its financial results for the quarter ended ...
07/26/16 05:29 PMWill MacroGenics, Inc. (NASDAQ:MGNX) Surprise This Quarter? - Investor Newswire
07/23/16 09:06 AMMacroGenics Inc (NASDAQ:MGNX) Upside Stock Technicals at Extreme Strength - CML News
07/22/16 08:08 AMAre Analysts Bearish MacroGenics Inc (NASDAQ:MGNX) After Last Week? - Consumer Eagle
07/22/16 08:08 AMMacroGenics Inc. (MGNX) Jumps 6.43% on July 20 - Equities.com
07/19/16 10:50 AMHeightened Volatility Spotted on Shares of: MacroGenics, Inc. (NASDAQ:MGNX) - Engelwood Daily
07/19/16 10:50 AMStock in Positive Territory for the Quarter: MacroGenics, Inc. (NASDAQ:MGNX) - Engelwood Daily
07/18/16 10:29 AMShare Performance Summary for: MacroGenics, Inc. (NASDAQ:MGNX) - Press Telegraph
07/17/16 04:40 PMMacroGenics, Inc. (NASDAQ:MGNX) Broker Price Targets For The Coming Week - Fiscal Standard
07/15/16 09:37 AMCrowd Rating and Earnings Recap for MacroGenics, Inc. (NASDAQ:MGNX) - Telanagana Press
07/14/16 05:27 PMMacroGenics, Inc. (NASDAQ:MGNX) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/14/16 05:27 PMHow Analysts Rated MacroGenics Inc (NASDAQ:MGNX) Last Week? - Consumer Eagle
07/12/16 09:34 AMMacroGenics, Inc. (NASDAQ:MGNX) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/12/16 09:34 AMTrading Performance and Target Watch for MacroGenics, Inc. (NASDAQ:MGNX) - Press Telegraph
07/11/16 09:49 AMTraders Are Watching: MacroGenics, Inc. (NASDAQ:MGNX), Cymabay Therapeutics, Inc. (NASDAQ:CBAY), Biogen Inc ... - KC Register
07/11/16 09:49 AMStock on the Rise for the Quarter: MacroGenics, Inc. (NASDAQ:MGNX) - Engelwood Daily
07/11/16 09:49 AMNext Weeks Broker Price Targets For MacroGenics, Inc. (NASDAQ:MGNX) - Fiscal Standard
07/11/16 09:49 AMStock Performance Rundown on: MacroGenics, Inc. (NASDAQ:MGNX) - Press Telegraph
07/08/16 08:03 AMWall Street Ratings and Target Price Views on MacroGenics, Inc. (NASDAQ:MGNX) - Telanagana Press
07/07/16 05:12 PMMacroGenics, Inc. (NASDAQ:MGNX) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/06/16 09:48 AMNew Broker Ratings For MacroGenics, Inc. (NASDAQ:MGNX) - FTSE News
07/06/16 09:48 AMStock Tracking Down This Month; Investor Alert on MacroGenics, Inc. (NASDAQ:MGNX) - Engelwood Daily
07/06/16 09:48 AMStock Rating Watch and Earnings Insight for MacroGenics, Inc. (NASDAQ:MGNX) - Press Telegraph
07/04/16 04:36 PMShare Performance Recap for: MacroGenics, Inc. (NASDAQ:MGNX) - Press Telegraph
06/30/16 05:30 PMShare Update and Earnings Review for MacroGenics, Inc. (NASDAQ:MGNX) - Press Telegraph
06/30/16 05:30 PMMacroGenics, Inc. (NASDAQ:MGNX) Company Rating and Target Watch - Telanagana Press
06/30/16 05:30 PMHow Analysts Feel About MacroGenics Inc (NASDAQ:MGNX)? - Engelwood Daily
06/28/16 05:02 PMMacrogenics Incorporated (NASDAQ:MGNX) Sellers Increased By 1.33% Their Shorts - Engelwood Daily
06/28/16 05:02 PMCheck on Share Volatility: MacroGenics, Inc. (NASDAQ:MGNX) - Engelwood Daily
06/28/16 05:02 PMMacroGenics Inc (NASDAQ:MGNX)'s Company Shares Decreased 5.92% After High Volatility - Press Telegraph
06/28/16 06:30 AMMacroGenics Announces Closing of Collaboration and License Agreement with Janssen to Develop MGD015 - [GlobeNewswire] - Rockville, MD, June 28, 2016-- MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of ...
06/25/16 04:47 PMMacroGenics Inc. (MGNX) Jumps 8.2% on June 23 - Equities.com
06/22/16 09:52 AMRecently Issued Stock Ratings For MacroGenics, Inc. (NASDAQ:MGNX) - Fiscal Standard
06/20/16 05:31 AMMacroGenics, Inc. (NASDAQ:MGNX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/14/16 04:55 PMAnalysts Have Conflicting Sentiments on These Healthcare Companies: MacroGenics Inc (NASDAQ: MGNX), Seattle ... - Analyst Ratings
06/10/16 05:09 AMMacroGenics Presents Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2016) - [at noodls] - Bispecific molecule based on DART® platform simultaneously targets B-cell antigens, CD32B and CD79B MGD010 was well tolerated at all dose levels with no serious adverse effects ROCKVILLE, Maryland, June ...
06/07/16 05:21 PMMacroGenics Inc. (MGNX) Jumps 6.9% on June 06 - Equities.com
06/06/16 08:51 AMPerformance Review for MacroGenics, Inc. (NASDAQ:MGNX) - HNN
06/04/16 05:10 PMWeekly Review: Eleven Biotherapeutics Inc (NASDAQ:EBIO), MacroGenics Inc (NASDAQ:MGNX) - Market News Call
06/03/16 05:37 PMMacrogenics Incorporated (NASDAQ:MGNX) Shorted Shares Increased By 3.36% - HNN
06/02/16 05:30 PMMacroGenics Inc. (MGNX) Jumps 5.78% on June 02 - Equities.com - MacroGenics Inc. (MGNX) Jumps 5.78% on June 02Equities.comMacroGenics Inc. (MGNX) was among the biggest gainers on the Russell 2000 for Thursday June 02 as the stock popped 5.78% to $27.44, representing a gain of $1.5 per share. Some 261,482 shares traded hands on 2,713 trades, compared with an average ...and more »
06/02/16 08:02 AMBuy, Sell Or Hold Rating For MacroGenics, Inc. (NASDAQ:MGNX)? - Share Trading News - Buy, Sell Or Hold Rating For MacroGenics, Inc. (NASDAQ:MGNX)?Share Trading News05/18/2016 – MacroGenics, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 47 price target on the stock. 04/07/2016 – BTIG Research began new coverage on MacroGenics, Inc. giving the company a “buy” rating.and more »
06/01/16 08:00 AMStock Review and Earnings Check on MacroGenics, Inc. (NASDAQ:MGNX) - HNN - Stock Review and Earnings Check on MacroGenics, Inc. (NASDAQ:MGNX)HNNCompany earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting MacroGenics, Inc. (NASDAQ:MGNX) to report quarterly EPS of $-0.71. The company's next earnings report is expected to be published on or ...and more »
05/29/16 06:57 PMMacrogenics Incorporated (NASDAQ:MGNX) Shorted Shares Increased 3.36% After Market Selling - HNN - Macrogenics Incorporated (NASDAQ:MGNX) Shorted Shares Increased 3.36% After Market SellingHNNThe short interest to Macrogenics Incorporated's float is 8%. The stock increased 2.30% or $0.55 on May 27, hitting $24.5. About 233,197 shares traded hands. MacroGenics Inc (NASDAQ:MGNX) has declined 13.12% since October 22, 2015 and is ...and more »
05/25/16 12:45 AMEarnings Review and Stock Rundown for MacroGenics, Inc. (NASDAQ:MGNX) - Wall Street Hints and News - Earnings Review and Stock Rundown for MacroGenics, Inc. (NASDAQ:MGNX)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting MacroGenics, Inc. (NASDAQ:MGNX) to post ...and more »
05/23/16 12:20 PMStock Rating Review for MacroGenics, Inc. (NASDAQ:MGNX) - Wall Street Hints and News - Stock Rating Review for MacroGenics, Inc. (NASDAQ:MGNX)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1.33 on shares of MacroGenics, Inc. (NASDAQ:MGNX). Covering analysts ...and more »
05/22/16 06:29 PMMacroGenics, Inc. (NASDAQ:MGNX) Reports Basic Consolidated EPS At $-0.6333 - Investor Newswire - MacroGenics, Inc. (NASDAQ:MGNX) Reports Basic Consolidated EPS At $-0.6333Investor NewswireFrom the parent firm, MacroGenics, Inc. (NASDAQ:MGNX) diluted EPS came at $-0.6333 for the year ended 2015-12-31. For the quarter ended 2015-12-31 it came at $-0.6333. MacroGenics, Inc. (NASDAQ:MGNX) posted net basic EPS of $-0.63 for the year ...
05/22/16 06:29 PMMacroGenics Inc (MGNX) is Trading Higher on Unusual Volume for May 19 - Equities.com - MacroGenics Inc (MGNX) is Trading Higher on Unusual Volume for May 19Equities.comMacroGenics Inc (MGNX) experienced unusually high volume on May. 19, as the stock gained 1.23% to a closing price of $21.32. The stock saw 483,289 shares trade hands over the course of the day on 3,488 trades. Given that the stock's average daily ...and more »
05/20/16 07:01 PMMacroGenics Inc (MGNX) Jumps 6.05% on May 20 - Equities.com - MacroGenics Inc (MGNX) Jumps 6.05% on May 20Equities.comMacroGenics Inc (MGNX) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 6.05% to $22.61, representing a gain of $1.29 per share. Some 288,323 shares traded hands on 2,984 trades, compared with an average ...and more »
05/20/16 01:20 PMMACROGENICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -

Social

About MacroGenics

MacroGenics logoMacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment. It develops therapeutic product candidates using its antibody-based technology platforms and in partnership with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily against various cancers. Its product candidates include margetuximab, enoblituzumab, MGD006, MGD007, MGD011, MGD009, MGD013, MGD010, teplizumab and MGD014. Its clinical product candidate, margetuximab, is a monoclonal antibody directed against human epidermal growth factor receptor 2, (HER2), including certain types of breast and gastroesophageal cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MGNX
  • CUSIP:
Key Metrics:
  • Previous Close: $29.96
  • 50 Day Moving Average: $26.55
  • 200 Day Moving Average: $21.42
  • P/E Ratio: N/A
  • P/E Growth: 0.04
  • Market Cap: $1.03B
  • Beta: 2.78
  • Current Year EPS Consensus Estimate: $-2.29 EPS
  • Next Year EPS Consensus Estimate: $-3.48 EPS
Additional Links:
MacroGenics (NASDAQ:MGNX) Chart for Thursday, July, 28, 2016